Ïà½ÏÓÚÉÏÁ½´Î¼ìÑé½á¹û£¬ÐÂÔö¼ÓÁËCCPµÄ¼ì²â½á¹û£¬CCP½á¹ûΪ60£¬Ã÷ÏÔ¸ßÓÚÕý³£½á¹û£¬RFδ¼ûÃ÷ÏÔÉý¸ßÏÖÏó¡£
ÄÇô¾¿¾¹CCPÊÇʲô£¬ÎªÊ²Ã´»áÉý¸ß£¬¶øÕë¶ÔÓÚÀà·çʪָ±êRF´ÓʼÖÁÖÕΪʲôÊÇÕý³£µÄ£¿´ø×ÅÏÂÃæµÄÒÉÎÊ£¬ÎÒÃÇÏÈÁ˽âÏÂRFºÍCCP¡£
Àà·çʪ¹Ø½ÚÑ×£¨RA£©ÊÇÒ»ÖÖÒÔÇÖÊ´ÐԹؽÚÑ×ΪÖ÷ÒªÁÙ´²±íÏÖµÄ×ÔÉíÃâÒß²¡£¬¿É·¢ÉúÓÚÈκÎÄêÁä¡£
¸ù¾ÝÁ÷ÐÐÐÔ²¡Ñ§µ÷²é£¬RAµÄÈ«Çò·¢²¡ÂÊΪ 0.5%~1%[1]£¬Öйú´ó½µØÇø·¢²¡ÂÊΪ0.42%£¬×Ü»¼²¡ÈËȺԼ500Íò[2]£¬ÎÒ¹úRA»¼ÕßÔÚ²¡³Ì1~5Äê¡¢5~10Äê¡¢10~15Äê¼°¡Ý15ÄêµÄÖ²ÐÂÊ·Ö±ðΪ18.6%¡¢43.5%¡¢48.1%¡¢61.3%£¬Ëæ×Ų¡³ÌµÄÑÓ³¤£¬²Ð¼²¼°¹¦ÄÜÊÜÏÞ·¢ÉúÂÊÉý¸ß[3]¡£RAÔçÕï¡¢ÔçÖΣ¬¿ÉÒÔ´ó´ó½µµÍÖ²ÐÂÊ¡£

Àà·çʪÒò×ÓRFÊǵÚÒ»¸ö±»·¢ÏÖÕï¶ÏÀà·çʪ¹Ø½ÚÑ×µÄÖØÒªÖ¸±ê£¬ÓÉÈËÌåBϸ°û²úÉú£¬³öÏÖÔÚ60%~80%µÄÀà·çʪ¹Ø½ÚÑ×»¼ÕßѪÇåÖС£
¶àÏîÑо¿Ö¤ÊµRFÔÚÀà·çʪ¹Ø½ÚÑ×»¼ÕßѪÇåÖÐÑôÐÔÂʺܸߣ¬¶øÔÚÆäËûÀàÐ͹ؽÚÑס¢·Ç·çʪÐÔ¼²²¡¼°½¡¿µÈËȺÖÐÑôÐÔÂʽϵͣ¬ÈÔÓÐ20%~40%µÄÀà·çʪ¹Ø½ÚÑ×»¼ÕßRFΪÒõÐÔ£¬Í¬Ê±ÉÙÊýÕý³£ÈËȺÖÐRFÒ²¿ÉÄܳÊÑôÐÔ¡£
Òò´ËÔÚÁÙ´²Õï¶Ï²»ÄÜÔçÆÚÕï¶ÏRA¡£ÁÙ´²Éϼ±ÐèÀà·çʪÐԹؽÚÑ×ÔçÆÚ±êÖ¾ÎÓÃÓÚÀà·çʪÐԹؽÚÑ×µÄÔçÆÚɸ²é¡£

¿¹»·¹Ï°±ËáëÄ¿¹Ìå(anti-cycliccitrullinated peptide antibody, anti-ccp antibody, Anti-CCP)£¬Óֳơ°¿¹CCP¿¹Ì塱£¬ÊôÓÚ¿¹½Çµ°°×¿¹Ì壬Æäº¬Óа±»ùËá¡¢¹Ï°±ËáµÄ²Ð»ù£¬¶ÔÀà·çʪ¹Ø½ÚÑ×»¼Õß¾ßÓÐÁ¼ºÃµÄÌØÒìÐÔ£¬ÁÙ´²ÉÏÖ÷ÒªÓ¦ÓÃÓÚRAµÄÔçÆÚɸ²éºÍ¼ø±ð£¬ÎªÁÙ´²Õï¶ÏÀà·çʪÐԹؽÚÑ×ÌØ±ðÊÇÔçÆÚÌṩÁ˾޴ó¼ÛÖµ¡£
¹ØÓÚCCPÓÖÓÐÄÄЩÁÙ´²Ó¦Óã¿
1¡¢ÔçÆÚÕï¶Ï
CCP±ÈÀà·çʪ¹Ø½ÚÑ×µÄÁÙ´²±íÏÖÔç1-14Ä꣬¸üÊʺϽ¡¿µÈËȺµÄÌå¼ìɸ²éºÍ¸ßΣÈËȺµÄÔçÆÚÕï¶Ï[4]¡£
2¡¢RAµÄ¼ø±ðÓëÕï¶Ï
CCP¶ÔÓÚÀà·çʪ¼²²¡µÄÌØÒìÐԸߴï96%£¬¿É×÷ΪÆäËû¼²²¡µ¼ÖµĹؽÚÑ׵ļø±ðÕï¶ÏµÄÖ¸±êÖ®Ò»¡£
CCP×÷ΪÀà·çʪÕï¶ÏµÄÐÂÐͱêÖ¾ÎÒѾ±»Ñ¡Èë¹úÄÚÍâȨÍþÕï¶Ï±ê×¼£¬2010Ä꣬ÃÀ¹ú·çʪ²¡Ñ§»á£¨ACR£©ºÍÅ·ÖÞ¿¹·çʪ²¡ÁªÃË£¨EULAR£©ÍƳö¡¶RAеķÖÀà±ê×¼¼°Æä·½·¨Ñ§¡·£¬ÍƼö½«CCP×÷ΪÕï¶Ï±ê×¼Ö®Ò»£¬2012Ä꣬ÎÒ¹úÍÆ³öÔçÆÚÀà·çʪ¹Ø½ÚÑ׵ķÖÀàÕï¶Ï±ê×¼£¬Ò²°üº¬CCPµÄ¼ì²â¡£
ÔçÆÚÖÎÁÆÊÇRA×îÖØÒªµÄÖÎÁƲßÂÔÖ®Ò»£¬ÔçÆÚ»ý¼«ÖÎÁÆÄÜ×èÖ¹¹Ø½Ú±»ÆÆ»µ£¬¼õÉÙÖ²ÐÂÊ¡£CCP×÷ΪÀà·çʪÐÔ¼²²¡ÐÂÐÍÖ¸±ê£¬ÒѾ±»¹ã·ºÊ¹Óã¬ÓÈÆäÔÚÉú»¯¼ì²âƽ̨ÉÏ£¬²âÊÔËٶȿ죬ÁªºÏRF¼ì²â¿ÉÒÔÌá¸ß¼ì³öÂʼ°ÌØÒìÐÔ£¬¸üÓÐÖúÓÚÀà·çʪÔçɸ¡¢ÔçÕï¡¢ÔçÖΡ£
